Skip to main content
Erschienen in: Indian Journal of Gastroenterology 5/2023

23.08.2023 | Editorial

Thrombophilia testing in splanchnic venous thrombosis: Decoding a conundrum

verfasst von: Akash Shukla, Sidharth Harindranath

Erschienen in: Indian Journal of Gastroenterology | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Excerpt

We read with great interest the article by Giri et al. analyzing the prevalence of acquired and inherited thrombophilia among Indian patients with non-cirrhotic portal vein thrombosis (PVT) and Budd-Chiari syndrome (BCS). The authors reported that the thrombophilia profile in Indian patients with abdominal vein thrombosis is different as compared to the west with a lower prevalence of prothrombotic conditions in patients with BCS. At least one prothrombotic condition was seen in 46.2% (28.7–63.7) of patients with PVT and 44.9% (37.3–60.7) of patients with BCS. Most common condition seen in patients with PVT was hyperhomocystinemia, whereas, in patients with BCS, protein C deficiency was the most common [1]. This study sheds light on the contentious topic of thrombophilia testing in patients with splanchnic venous thrombosis and ends up generating many questions while answering a few. …
Literatur
4.
Zurück zum Zitat Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004–8.CrossRefPubMedPubMedCentral Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004–8.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–6.CrossRefPubMed Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–6.CrossRefPubMed
6.
Zurück zum Zitat Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994;343:1535–6.CrossRefPubMed Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994;343:1535–6.CrossRefPubMed
7.
Zurück zum Zitat Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106:3377–9.CrossRefPubMedPubMedCentral Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106:3377–9.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.CrossRefPubMed Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.CrossRefPubMed
9.
Zurück zum Zitat Shukla A, Shreshtha A, Mukund A, et al. Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2021;15:531–67.CrossRefPubMed Shukla A, Shreshtha A, Mukund A, et al. Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2021;15:531–67.CrossRefPubMed
10.
Zurück zum Zitat Rodríguez-Leal GA, Morán S, Corona-Cedillo R, Brom-Valladares R. Portal vein thrombosis with protein C-S deficiency in a non-cirrhotic patient. World J Hepatol. 2014;6:532–7.CrossRefPubMedPubMedCentral Rodríguez-Leal GA, Morán S, Corona-Cedillo R, Brom-Valladares R. Portal vein thrombosis with protein C-S deficiency in a non-cirrhotic patient. World J Hepatol. 2014;6:532–7.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Parkash O, Khan A, Hamid S. Clinical characteristics and out- come of Budd-Chiari syndrome at a tertiary care hospital in Pakistan. J Coll Phys Surg-Pak JCPSP. 2017;27:301–4. Parkash O, Khan A, Hamid S. Clinical characteristics and out- come of Budd-Chiari syndrome at a tertiary care hospital in Pakistan. J Coll Phys Surg-Pak JCPSP. 2017;27:301–4.
12.
Zurück zum Zitat Tasneem AA, Soomro GB, Abbas Z, Luck NH, Hassan SM. Clinical presentation and predictors of survival in patients with Budd Chiari syndrome: experience from a tertiary care hospital in Pakistan. JPMA J Pak Med Assoc. 2015;65:120–4.PubMed Tasneem AA, Soomro GB, Abbas Z, Luck NH, Hassan SM. Clinical presentation and predictors of survival in patients with Budd Chiari syndrome: experience from a tertiary care hospital in Pakistan. JPMA J Pak Med Assoc. 2015;65:120–4.PubMed
13.
Zurück zum Zitat Westbrook RH, Lea NC, Mohamedali AM, et al. Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation. Liver Transpl. 2012;18:819–27.CrossRefPubMed Westbrook RH, Lea NC, Mohamedali AM, et al. Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation. Liver Transpl. 2012;18:819–27.CrossRefPubMed
14.
Zurück zum Zitat Fan J, Wang Q, Luo B, et al. Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: a hospital-based observational study. J Gastroenterol Hepatol. 2020;35:1215–22.CrossRefPubMed Fan J, Wang Q, Luo B, et al. Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: a hospital-based observational study. J Gastroenterol Hepatol. 2020;35:1215–22.CrossRefPubMed
15.
Zurück zum Zitat Nowak-Göttl U, Junker R, Kreuz W, et al. Childhood thrombophilia study group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood. 2001;97:858–62.CrossRefPubMed Nowak-Göttl U, Junker R, Kreuz W, et al. Childhood thrombophilia study group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood. 2001;97:858–62.CrossRefPubMed
Metadaten
Titel
Thrombophilia testing in splanchnic venous thrombosis: Decoding a conundrum
verfasst von
Akash Shukla
Sidharth Harindranath
Publikationsdatum
23.08.2023
Verlag
Springer India
Erschienen in
Indian Journal of Gastroenterology / Ausgabe 5/2023
Print ISSN: 0254-8860
Elektronische ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-023-01443-8

Weitere Artikel der Ausgabe 5/2023

Indian Journal of Gastroenterology 5/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.